Cosmo Pharmaceuticals N.V, an AI-powered healthcare and speciality pharma,  has announced a compelling topline results from its two pivotal Phase III trials of clascoterone 5% topical solution for male androgenetic alopecia (AGA, also known as male-pattern hair loss), marking a potential first major therapeutic breakthrough in hair-loss treatment in more than three decades. more